269
During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
 four out of the seven patients: Subject; four out of the seven: Subject.Population; moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia: Effect; During clarithromycin coadministration: Treatment; carbamazepine: Treatment; During: Treatment.Time_elapsed; clarithromycin: Treatment.Drug; carbamazepine: Treatment.Drug; clarithromycin: Combination.Drug; carbamazepine: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 four out of the seven patients: Subject; four out of the seven: Subject.Population; moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia: Effect; During clarithromycin coadministration: Treatment; carbamazepine: Treatment; During: Treatment.Time_elapsed; clarithromycin: Treatment.Drug; carbamazepine: Treatment.Drug; clarithromycin: Combination.Drug; carbamazepine: Combination.Drug